Pharmaceutical Technology, February 2015 Issue (PDF)

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-02-02-2015
Volume 39
Issue 2

Click the title above to open the Pharmaceutical Technology February 2015 issue in an interactive PDF format.

External Link - PharmTech_NA_Feb2015.pdf

Articles in this issue
HAPR0110_CATLAB-Integrated-Micro-reactor_main.jpg
Hiden Analytical Combination Spectrometer Increases Repeatability
Ross-Bow-Tie-Dispersers_main.jpg
Ross Disperser Maintains Consistency
Ultra_Series_30kW_no_words_main.jpg
Radio Frequency Dryer Improves Efficiency
iRVision-from-FANUC_main.jpg
FANUC Robot Enhances Cycles Per Second
Fig2b_web.jpg
Preventing Tablet Tooling Problems
Chiral Resolution with and without Resolving Agents
Chiral Resolution with and without Resolving Agents
FDA Sets Agenda for 2015 Guidance Development
Cures Require Compromise
mainimage-laboratory-assay-in-a-microtiter-plate-gettyimages.jpg
Ligand-Binding Assays and the Determination of Biosimilarity
Milmo_Sean.jpg
Labeling of Biosimilars
FDA Sets Policies to Enhance Drug Security and Safety
Gauging the CMO Biosimilar Opportunity
Sam-de-Costaheadshot.jpg
Particle Engineering for Bioavailability Enhancement
Finding Opportunities in Brazil
Finding Opportunities in Brazil
Enhancing Dissolution of Poorly Soluble Drugs through Jet-Milling
Enhancing Dissolution of Poorly Soluble Drugs through Jet-Milling
Recent Videos
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Related Content
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

FDA Grants Fast Track Designation to Q32 Bio Treatment for Alopecia Areata

Patrick Lavery
April 30th 2025
Article

Bempikibart (ADX-914) is a human anti-IL-7Rα antibody that blocks the IL-7 and TSLP pathways, which have been implicated in driving T cell-mediated pathological processes in autoimmune diseases.

Site Logo

Transformations in Drug Development for Cell and Gene Therapies

PPD;Thermo Fisher Scientific
March 28th 2025
Podcast

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

CHMP Recommends argenx Treatment for Chronic Inflammatory Demyelinating Polyneuropathy

Patrick Lavery
April 28th 2025
Article

The company said that Vyvgart (efgartigimod alfa) is the first novel mechanism of action for CIDP treatment in more than 30 years.

Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang

Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang

PPD;Thermo Fisher Scientific
March 28th 2025
Podcast

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.

Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept. | Image Credit: © Dilok - stock.adobe.com

Debiopharm, Oncodesign Agree to Use Non-Invasive Technology for Preclinical Research

Patrick Lavery
April 25th 2025
Article

The AbYlink technology enables a seamless, reproducible conjugation of payloads to antibodies or ADCs.

Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept | Image Credit: © Dilok – © Dilok - stock.adobe.com

CN Bio Forms Strategic Partnership with Pharmaron to Develop OOC Technologies

Feliza Mirasol
April 25th 2025
Article

Under the partnership, Pharmaron will validate and promote the application of CN Bio’s PhysioMimix technology and will integrate OOC technologies into its R&D platform.